1 week Ago By Defense World Staff
Xenon Pharmaceuticals Inc. ( NASDAQ:XENE – Free Report ) – Equities research analysts at Wedbush issued their FY2029 EPS estimates for Xenon Pharmaceuticals in a report issued on Thursday, January 23rd. Wedbush analyst L.
Chico forecasts that the biopharmaceutical company will post earnings of $5.54 per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.
13) per share. Other equities analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $60.
00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Raymond James reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th.
Finally, HC Wainwright reaffirmed a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock.
Based on data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $56.00. Xenon Pharmaceuticals Trading Down 0.
1 % Shares of NASDAQ:XENE opened at $39.95 on Friday. The company has a market cap of $3.
05 billion, a price-to-earnings ratio of -14.17 and a beta of 1.20.
The company has a 50-day moving average price of $40.20 and a 200-day moving average price of $40.82.
Xenon Pharmaceuticals has a 12 month low of $35.53 and a 12 month high of $50.99.
Xenon Pharmaceuticals ( NASDAQ:XENE – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.
82) by $0.01. During the same quarter in the prior year, the company earned ($0.
73) EPS. Institutional Investors Weigh In On Xenon Pharmaceuticals A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC grew its holdings in shares of Xenon Pharmaceuticals by 2.
2% during the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after buying an additional 149,511 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in shares of Xenon Pharmaceuticals by 2.
3% during the second quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock valued at $172,315,000 after buying an additional 97,732 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Xenon Pharmaceuticals by 0.
4% during the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock valued at $151,317,000 after buying an additional 15,226 shares during the last quarter. Braidwell LP grew its holdings in shares of Xenon Pharmaceuticals by 5.
7% during the third quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company’s stock valued at $106,585,000 after buying an additional 146,682 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Xenon Pharmaceuticals by 144.
2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after buying an additional 1,507,135 shares during the last quarter. Hedge funds and other institutional investors own 95.
45% of the company’s stock. Insider Buying and Selling In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $41.
08, for a total value of $200,922.28. Following the sale, the director now owns 23,573 shares in the company, valued at approximately $968,378.
84. This represents a 17.18 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.
21, for a total transaction of $770,997.89. The disclosure for this sale can be found here .
5.52% of the stock is owned by insiders. About Xenon Pharmaceuticals ( Get Free Report ) Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. Further Reading Five stocks we like better than Xenon Pharmaceuticals 3 Ways To Invest In Coffee, Other Than Drinking It Bloom Energy: Powering the Future With Decentralized Energy What is a SEC Filing? Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul 3 Home Improvement Stocks that Can Upgrade Your Portfolio Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
